-
Prusogliptin Tablets Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1 innovative drug Prusogliptin Tablets (trade name: 善泽平) of CSPC OUYI PHARMACEUTICAL CO., LTD. is approved for marketing by China NMPA.
-
Innovative TCM Qifang Bitong Tablets Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1.1 innovative traditional Chinese medicine (TCM) Qifang Bitong Tablets of Beijing Yiling Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Limertinib Tablets Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1 innovative drug Limertinib Tablets (trade name: 奥壹新) of Jiangsu Osaikang Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Senaparib Capsules Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1 innovative drug Senaparib Capsules (trade name: 派舒宁/Paishuning) of Shanghai Inpai Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Efsubaglutide Alfa Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Efsubaglutide Alfa Injection (trade name: 怡诺轻) of Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. is approved for marketing by China NMPA.
-
Phakic Intraocular Lens Approved for Marketing
2025-06-11
Recently, the innovative product "Phakic Intraocular Lens" of Eyebright Medical Technology (Beijing) Co., Ltd. is approved by China NMPA.
